EpiVario, Inc.

EpiVario is a preclinical stage biotechnology company focusing on neuropsychiatric disorders. Our co-founders, Dr. Shelley Berger and Dr. Philipp Mews, are leaders in the field of neuroepigenetics. They identified a key metabolic enzyme that functions within the nucleus of neurons to activate genes critical for long term memory. This epigenetic mechanism plays a critical role in consolidating trauma-induced fear and stress responses and drug craving associated with addiction. Thus, providing a new target for treating memory-related neuropsychiatric disorders, such as PTSD and drug and alcohol addiction, and starting with nicotine addiction. An Expert Team Founded by epigeneticists at the University of Pennsylvania, EpiVario’s team leverages deep expertise in epigenetics and neuroscience, along with the commercialization of novel drugs. EpiVario’s co-founders are known and respected leaders in their fields, with more than 30 years of combined experience. A Strong Intellectual Property Portfolio EpiVario currently has PCT and U.S. patents pending, both related to the Company’s novel approach to targeting the ACSS2 gene. About Addiction and PTSD PTSD is a psychiatric disorder that can develop as a response to experiencing or witnessing a traumatic event, such as interpersonal violence, combat, or a life-threatening accident or natural disaster. Core features of PTSD include re-experiencing symptoms (i.e., intrusive memories, flashbacks, and nightmares), avoidance of reminders of the trauma, negative thoughts and feelings (e.g., amnesia for aspects of the trauma, anhedonia, withdrawal, exaggerated self-blame), and increased arousal (i.e., insomnia, irritability, poor concentration, hypervigilance). The severity of PTSD symptoms can intensify through cycles of memory recall and reconsolidation.